Abstract:Abstract Purpose: Stimulator of interferon genes (STING) is an upstream regulator of interferon and NF-κB, the key mediators of immune and inflammatory responses associated with cancer, triggered by cytosolic DNA. Downregulation of STING in breast tumor tissues has been reported. STING elicits caspase-8-dependent cell apoptosis via NF-κB in breast cancer cells. STING agonists are considered as potent anti-cancer agents. The current study aims to assess the biological functions of STING in breast cancer progression. Experimental design: Data of mRNA expression levels and recurrence-free survival in patients with breast cancer from The Cancer Genome Atlas and Kaplan Meier-plotter databases were analyzed. Transwell assays were used to evaluate cell migrated and invaded abilities. Sphere formation was performed in stem cell-selective medium and ultra-low attachment plates. Two STING agonists, ADU-S100 and diABZI STING agonist-1 trihydrochloride, were used for in vitro studies. The molecular events were examined by Western blot analysis. Results: Data from public database showed that lower transcripts levels of STING in Her2 and luminal B breast cancer tissues than normal breast tissues. Luminal-type breast cancer cell lines harbored low STING transcripts compared with other subtypes. Importantly, breast cancer patients with low expression levels of STING was associated with worse recurrence-free survival. Results of immunoblotting indicated that breast cancer cell lines have lower STING protein expressions than normal MCF10A cells. Knockdown of STING led to aggressive phenotypes of MCF10A and BT474 cells. In contrast, overexpression of STING suppressed the abilities of migration, invasion and sphere formation of MCF7 and BT474 cells. The markers of epithelial were increased while the markers of mesenchymal and stemness were decreased by STING overexpression. STING agonist slightly suppressed cell viability of breast cancer cells but not MCF10A cells. Treatment of STING agonists reduced cell migrated ability with upregulation of E-cadherin and γ-catenin. Conclusion: These findings suggest that STING serves tumor-suppressive effects in breast cancer. Citation Format: Chun-Yu Liu, Ji-Lin Chen, Chun-Teng Huang, Pei-Yi Chu, Mei-Fang Tseng, Yu-Hsuan Lee, Wan-Lun Wang, Ling-Ming Tseng. Pleiotropic anti-cancer effects of STING in estrogen receptor positive breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2486.

Hsa-miR-181a-2-3p inhibits the oncogenicity of colon cancer by directly targeting STING

Upregulation of microRNA-383 inhibits the proliferation, migration and invasion of colon cancer cells.

Exosomal Mir-183-5p Promotes Angiogenesis in Colorectal Cancer by Regulation of FOXO1

miR-181d Inhibits Proliferation and Promotes Apoptosis in Colon Cancer Cells

miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling

MiR-182-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-C

MicroRNA-185 suppresses growth and invasion of colon cancer cells through inhibition of the hypoxia‑inducible factor-2α pathway in vitro and in vivo.

MicroRNA-363-3p inhibits colorectal cancer progression by targeting interferon-induced transmembrane protein 1

Pleiotropic anti-cancer effects of STING in estrogen receptor positive breast cancer cells.

Mir-193B Directly Targets STMN1 and Inhibits the Malignant Phenotype in Colorectal Cancer.

miR-129-2-3p inhibits colon cancer cell proliferation by down-regulating the expression of BZW1

Cutting Edge: STING Mediates Protection Against Colorectal Tumorigenesis by Governing the Magnitude of Intestinal Inflammation

Mir-218 Inhibits the Invasion and Migration of Colon Cancer Cells by Targeting the PI3K/Akt/mTOR Signaling Pathway

hsa‐miR‐15a‐5p inhibits colon cell carcinoma via targeting CCND1

STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer

Decreased Expression of STING Predicts Poor Prognosis in Patients with Gastric Cancer

Microrna-33a and Let-7e Inhibit Human Colorectal Cancer Progression by Targeting St8sia1

Targeting the STING Pathway in Tumor-Associated Macrophages Regulates Innate Immune Sensing of Gastric Cancer Cells.

miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses

MicroRNA-181a Promotes Tumor Growth and Liver Metastasis in Colorectal Cancer by Targeting the Tumor Suppressor WIF-1

MiR-181d Inhibits Cell Proliferation and Metastasis Through PI3K/AKT Pathway in Gastric Cancer.